A month after receiving a blood transfusion an immunocompromised male patient develops a fever,

Questions 32

ATI RN

ATI RN Test Bank

ATI Pharmacology Practice Exam B Questions

Question 1 of 5

A month after receiving a blood transfusion an immunocompromised male patient develops a fever,

Correct Answer: C

Rationale: A month after receiving a blood transfusion, the development of a fever in an immunocompromised patient can be indicative of graft-versus-host disease (GVHD). GVHD is a condition where the donor immune cells attack the recipient's tissues, manifesting as fever, rash, liver dysfunction, and gastrointestinal symptoms. It typically occurs a few weeks to several months after a blood transfusion, especially in immunocompromised individuals. An allergic response to medication or myelosuppression would typically present earlier after the transfusion, while nothing related to the blood transfusion does not explain the fever in this context.

Question 2 of 5

What is the category status for the drug Omeprazole?

Correct Answer: B

Rationale: Omeprazole is classified as an anti-ulcer agent. It belongs to a class of medications known as proton pump inhibitors (PPIs) that work by reducing the amount of acid produced in the stomach. Omeprazole is commonly used to treat conditions such as gastroesophageal reflux disease (GERD), ulcers, and Zollinger-Ellison syndrome. It is not a laxative, anti-heartburn medication, or antianemic drug.

Question 3 of 5

Which of the following is NOT a therapeutic effect of Montelukast?

Correct Answer: D

Rationale: Montelukast is a medication commonly used to treat asthma and allergic rhinitis. Its therapeutic effects include decreased frequency and severity of acute asthma attacks, decreased severity of allergic rhinitis, and decreased attacks of exercise-induced bronchoconstriction. However, Montelukast is not associated with treating anxiety attacks. Anxiety is a mental health condition that is typically managed with appropriate therapy and medication specifically designed for anxiety disorders.

Question 4 of 5

A drug that has both affinity and intrinsic activity

Correct Answer: D

Rationale: A drug that has both affinity and intrinsic activity is known as a partial agonist. Affinity refers to the drug's ability to bind to a receptor, while intrinsic activity is the drug's ability to activate the receptor and produce a response. A partial agonist binds to the receptor with affinity but only activates the receptor to a partial extent compared to a full agonist. This results in a less potent response compared to a full agonist but also blocks the full agonist's effects, making it act as an antagonist in the presence of a full agonist. In summary, a drug that has both affinity and intrinsic activity is classified as a partial agonist because it binds to the receptor and activates it but to a lesser extent than a full agonist.

Question 5 of 5

The pharmacological property of aspirin comes from its ability to inhibit the synthesis of :

Correct Answer: A

Rationale: Aspirin exerts its pharmacological effects by inhibiting the synthesis of eicosanoids. Eicosanoids are signaling molecules that play a key role in inflammation, pain, and fever. Specifically, aspirin inhibits the enzyme cyclooxygenase (COX), which is crucial for the production of prostaglandins from arachidonic acid. By blocking COX, aspirin reduces the formation of pro-inflammatory prostaglandins, ultimately leading to its anti-inflammatory, analgesic, and antipyretic effects. This mechanism also accounts for aspirin's ability to inhibit platelet aggregation, which is why it is commonly used as an antithrombotic agent.

Access More Questions!

ATI RN Basic


$89/ 30 days

ATI RN Premium


$150/ 90 days

Similar Questions